Ecopetrol
EC
Apple
AAPL
D.R. Horton
DHI
Meritage Homes
MTH
Lennar Corp
LEN
US Stock MarketDetailed Quotes
CMPS COMPASS Pathways
- 2.860
- -0.080-2.72%
Close Mar 31 16:00 ET
- 2.949
- +0.089+3.13%
Post 20:01 ET
265.05MMarket Cap-1.24P/E (TTM)
2.910High2.720Low1.19MVolume2.900Open2.940Pre Close3.38MTurnover1.66%Turnover RatioLossP/E (Static)92.67MShares9.97052wk High1.71P/B204.63MFloat Cap2.72052wk Low--Dividend TTM71.55MShs Float61.690Historical High--Div YieldTTM6.46%Amplitude2.720Historical Low2.845Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
COMPASS Pathways Stock Forum
Breakthrough Depression Treatment Reaches Critical Phase 3 Milestone: COMP360 Psilocybin Trial Fully Enrolled
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Wednesday, 26th March at 6:30 am
Highlights:
• Screening closed for all sites and final participants being scheduled for dosing
• On track for top-line 6-week primary endpoint results in late Q2
Compass Pathways plc (NASDAQ: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation,...
Breakthrough: Single Dose Psilocybin Fights Depression for 189 Days, New Study Shows
Can Compass Pathways' $140M Cash Infusion Offset Growing Losses in Psychedelic Treatment Race?
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
No comment yet